Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
5% nitrate · 1 trial · 1 indication
Response to a one second application of air from a standard dental unit syringe applied to the surface of hypersensitive tooth. After each stimuli participant rated the intensity of pain on a 100 millimeter VAS, on which 0 represented "no pain" and 100 represented the" worst pain imaginable". Change from baseline was calculated as mean score at the given time point minus mean score at baseline.
| Arm | Type | Description |
|---|---|---|
| 5% KNO3 solution | EXPERIMENTAL | Participants to apply 5% potassium nitrate solution to a single sensitive tooth for two minutes, in each of the five day treatment period. |
| 2.5% KNO3 solution | EXPERIMENTAL | Participants to apply 2.5% potassium nitrate solution to a single sensitive tooth for two minutes, in each of the five day treatment period. |
| Sterile Water | PLACEBO_COMPARATOR | Participants to apply sterile water to a single sensitive tooth for two minutes, in each of the five day treatment period. |
| Name | Type | Description |
|---|---|---|
| 5% Potassium nitrate | DRUG | 5% potassium nitrate solution |
| 2.5% Potassium nitrate | DRUG | 2.5% potassium nitrate solution |
| Sterile water | OTHER | Sterile water |
Inclusion Criteria: * Self-reported history of dentinal hypersensitivity lasting more than 6 months and a primary complaint of sensitive teeth * Three teeth that can be isolated that meet all of the following criteria at the screening visit: * Teeth showing signs of facial/cervical gingival recessi...
5% nitrate is an investigational small molecule being studied for the treatment of dentine hypersensitivity, a condition characterized by sharp pain in teeth when exposed to hot, cold, sweet, or acidic stimuli. It is currently in Phase 2 clinical development.
5% nitrate is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational treatment for dentine hypersensitivity.
5% nitrate is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness for treating dentine hypersensitivity.
5% nitrate has one completed Phase 2 clinical trial registered under NCT01115452, titled 'Efficacy of Potassium Nitrate Solution in Reducing Dentinal Hypersensitivity.' This randomized, double-blind, placebo-controlled trial enrolled 32 participants in the United States to evaluate the treatment's effect on dentine hypersensitivity.
5% nitrate is a formulation of potassium nitrate, as indicated by the clinical trial title 'Efficacy of Potassium Nitrate Solution in Reducing Dentinal Hypersensitivity.' The drug is being studied as a solution for the treatment of dentine hypersensitivity.